DK3713554T3 - Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdomme - Google Patents
Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdommeInfo
- Publication number
- DK3713554T3 DK3713554T3 DK18803724.6T DK18803724T DK3713554T3 DK 3713554 T3 DK3713554 T3 DK 3713554T3 DK 18803724 T DK18803724 T DK 18803724T DK 3713554 T3 DK3713554 T3 DK 3713554T3
- Authority
- DK
- Denmark
- Prior art keywords
- vidofludimus
- treatment
- autoimmune diseases
- chronic inflammatory
- dosage instructions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203407 | 2017-11-23 | ||
| PCT/EP2018/082272 WO2019101888A1 (en) | 2017-11-23 | 2018-11-22 | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3713554T3 true DK3713554T3 (da) | 2026-04-13 |
Family
ID=60452494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18803724.6T DK3713554T3 (da) | 2017-11-23 | 2018-11-22 | Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdomme |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20200360324A1 (da) |
| EP (2) | EP3713554B1 (da) |
| JP (2) | JP7231628B2 (da) |
| KR (1) | KR102788999B1 (da) |
| CN (1) | CN111343975A (da) |
| AU (1) | AU2018371177B2 (da) |
| BR (1) | BR112020009477A2 (da) |
| CA (1) | CA3083155A1 (da) |
| DK (1) | DK3713554T3 (da) |
| ES (1) | ES3068307T3 (da) |
| FI (1) | FI3713554T3 (da) |
| HR (1) | HRP20260592T1 (da) |
| IL (1) | IL274836B2 (da) |
| LT (1) | LT3713554T (da) |
| MA (1) | MA50790B1 (da) |
| MD (1) | MD3713554T2 (da) |
| MX (1) | MX2020005360A (da) |
| MY (1) | MY202409A (da) |
| PH (1) | PH12020550680A1 (da) |
| PT (1) | PT3713554T (da) |
| RS (1) | RS68050B1 (da) |
| SG (1) | SG11202002746YA (da) |
| SI (1) | SI3713554T1 (da) |
| SM (1) | SMT202600202T1 (da) |
| UA (1) | UA127354C2 (da) |
| WO (1) | WO2019101888A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127354C2 (uk) * | 2017-11-23 | 2023-07-26 | Іммунік Аґ | Спосіб профілактики або лікування хронічних запальних і/або аутоімунних захворювань відофлудимусом |
| ES2928418T3 (es) * | 2020-04-10 | 2022-11-17 | Inst Nat Sante Rech Med | Uso de vidofludimus para el tratamiento de infecciones por coronavirus |
| EP4487870A3 (en) | 2020-04-21 | 2025-03-12 | Immunic AG | Vidofludimus for use in the treatment or prevention of viral diseases |
| WO2022200615A1 (en) | 2021-03-26 | 2022-09-29 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Pyrimidine biosynthesis inhibitor combination for use in treating viral infections |
| KR20240007144A (ko) | 2021-04-09 | 2024-01-16 | 이뮤닉 아게 | 중수소화 dhodh 억제제 |
| US11877994B2 (en) * | 2021-08-02 | 2024-01-23 | Immunic Ag | Treatment of multiple sclerosis comprising DHODH inhibitors |
| UY40087A (es) | 2021-12-23 | 2023-06-30 | Immunic Ag | Inhibidores de DHODH que contienen un bioisóstero de ácido carboxílico. |
| CA3254754A1 (en) | 2022-06-01 | 2023-12-07 | Immunic Ag | TREATMENT OF ULCERATIVE COLITIS COMPRISING VIDOFLUDIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| EP4389138A1 (en) | 2022-12-22 | 2024-06-26 | Cytoki Pharma ApS | Dosage regimen for interleukin-22 derivatives |
| JP2025542282A (ja) | 2022-12-22 | 2025-12-25 | サイトカイ・ファーマ・アーペーエス | インターロイキン－２２誘導体の投薬レジメン |
| TW202444688A (zh) | 2023-03-29 | 2024-11-16 | 德商埃慕尼克股份公司 | 作為nurr1激動劑之維多氟地莫(vidofludimus)及相關結構 |
| US20240335405A1 (en) * | 2023-03-29 | 2024-10-10 | Immunic Ag | Vidofludimus and related structures acting as nurr1 agonists |
| UY40805A (es) | 2023-06-28 | 2025-01-15 | Immunic Ag | Inhibidores de dhodh heteroaromáticos |
| EP4761712A1 (en) | 2023-08-15 | 2026-06-24 | Immunic AG | Oral pharmaceutical dosage form providing immediate release of vidofludimus |
| WO2025215126A1 (en) | 2024-04-12 | 2025-10-16 | Immunic Ag | Synthesis of vidofludimus and its calcium salt |
| WO2026074007A1 (en) | 2024-10-02 | 2026-04-09 | Immunic Ag | Nurr1 agonists with replacement of the carboxylic acid or carboxamide moiety for use in the treatment of neurodegenerative diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
| TWI403506B (zh) * | 2008-06-16 | 2013-08-01 | Faes Farma Sa | 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類 |
| UA108760C2 (uk) * | 2010-07-01 | 2015-06-10 | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
| WO2015077535A2 (en) | 2013-11-22 | 2015-05-28 | Genzyme Corporation | Novel methods for treating neurodegenerative diseases |
| UA127354C2 (uk) | 2017-11-23 | 2023-07-26 | Іммунік Аґ | Спосіб профілактики або лікування хронічних запальних і/або аутоімунних захворювань відофлудимусом |
-
2018
- 2018-11-22 UA UAA202003733A patent/UA127354C2/uk unknown
- 2018-11-22 LT LTEPPCT/EP2018/082272T patent/LT3713554T/lt unknown
- 2018-11-22 MD MDE20200982T patent/MD3713554T2/ro unknown
- 2018-11-22 MX MX2020005360A patent/MX2020005360A/es unknown
- 2018-11-22 SI SI201831320T patent/SI3713554T1/sl unknown
- 2018-11-22 BR BR112020009477-3A patent/BR112020009477A2/pt not_active Application Discontinuation
- 2018-11-22 SG SG11202002746YA patent/SG11202002746YA/en unknown
- 2018-11-22 IL IL274836A patent/IL274836B2/en unknown
- 2018-11-22 RS RS20260519A patent/RS68050B1/sr unknown
- 2018-11-22 DK DK18803724.6T patent/DK3713554T3/da active
- 2018-11-22 CN CN201880073387.XA patent/CN111343975A/zh active Pending
- 2018-11-22 MA MA50790A patent/MA50790B1/fr unknown
- 2018-11-22 HR HRP20260592TT patent/HRP20260592T1/hr unknown
- 2018-11-22 JP JP2020527735A patent/JP7231628B2/ja active Active
- 2018-11-22 US US16/766,531 patent/US20200360324A1/en not_active Abandoned
- 2018-11-22 PT PT188037246T patent/PT3713554T/pt unknown
- 2018-11-22 WO PCT/EP2018/082272 patent/WO2019101888A1/en not_active Ceased
- 2018-11-22 ES ES18803724T patent/ES3068307T3/es active Active
- 2018-11-22 KR KR1020207017605A patent/KR102788999B1/ko active Active
- 2018-11-22 EP EP18803724.6A patent/EP3713554B1/en active Active
- 2018-11-22 MY MYPI2020002504A patent/MY202409A/en unknown
- 2018-11-22 SM SM20260202T patent/SMT202600202T1/it unknown
- 2018-11-22 FI FIEP18803724.6T patent/FI3713554T3/fi active
- 2018-11-22 CA CA3083155A patent/CA3083155A1/en active Pending
- 2018-11-22 AU AU2018371177A patent/AU2018371177B2/en active Active
- 2018-11-22 EP EP26165394.3A patent/EP4732905A3/en active Pending
-
2020
- 2020-05-22 PH PH12020550680A patent/PH12020550680A1/en unknown
-
2022
- 2022-11-22 US US17/992,162 patent/US11877995B2/en active Active
-
2023
- 2023-02-16 JP JP2023022183A patent/JP7660600B2/ja active Active
- 2023-12-06 US US18/531,121 patent/US12629347B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3240554T3 (da) | Blautia stercosis og wexlerae til anvendelse til behandling af inflammatoriske og autoimmune sygdomme | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3487505T3 (da) | Indgivelse og dosering af diaminophenothiaziner | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3812392T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3157531T3 (da) | Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| SMT202600202T1 (it) | Regime di dosaggio dividofludimus per l'uso nel trattamento di malattie infiammatorie e/o autoimmunicroniche | |
| DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
| DK3270909T3 (da) | Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko | |
| DK3612208T5 (da) | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3810128T3 (da) | Sammensætninger til behandling og/eller forebyggelse af proteinaggregeringssygdomme | |
| DK3630164T5 (da) | Dulaglutid til behandling af kronisk nyresygdom | |
| DK3157532T3 (da) | Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet | |
| DK3122743T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme | |
| DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme |